Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BME vs BST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BME Captures Overall Composite Edge (40.9 SELL vs 52.2 HOLD), While BST Leads 1–0 on Growth & Valuation Pillars

BME Overall Winner 6-Pillar Tally: BME 0 – 1 BST (5 Tie) Matrix Metrics: BME 2 – 2 BST

As of Nov 16, 2026, Blackrock Health Sciences Trust (BME) captures the overall head-to-head institutional edge over BlackRock Science and Technology Trust (BST) on higher Unified Composite conviction (40.9/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 2–2 (led by composite factor balance), while BST wins 1–0 across the 6-pillar growth and valuation breakdown. BME trades at $47.08 (N/M Forward P/E, N/A operating margin) versus BST at $43.09 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While BST currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. BME 40.9/100 SELL), BME captures the overall institutional head-to-head verdict (2–2 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: BME trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.7); meanwhile BST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BME vs BST
BME NYSE Head-to-Head Winner
Blackrock Health Sciences Trust
Institutional Equity
$47.08
-1.07% 1D
Market Cap $487.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.42β · 19% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 27.0 Fund 37.0 Flow 50.0 Mom 31.6
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.1% over 20 days), RSI 60
RSI-14: 59.7 · SMA20: $46.65 · SMA50: $45.16
BST NYSE
BlackRock Science and Technology Trust
Institutional Equity
$43.09
-3.36% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.55β · 41% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 49.0 Fund 54.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.9%), weak momentum, RSI 36
RSI-14: 35.8 · SMA20: $46.23 · SMA50: $48.19

6-Pillar Scorecard Institutional Category Breakdown (BME 0 – 1 BST)

Columns: Metric · BME · BST
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BST
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap $487.9M $1.4B
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BME (2) vs BST (2)
Institutional Metric BME BST Criterion Row Edge
Market Capitalization
Scale
$487.9M $1.4B Larger Scale BST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
89% ($38–$48) 47% ($35–$52) Stronger Trend BME
Beta / 30D Volatility
Risk Regime
0.42β · 19% Vol 1.55β · 41% Vol Lower Realized Risk BME
Unified Institutional Score
Composite Signal
40.9 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite BST
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BME +15.98 pp
BME: +6.98% · BST: -9.0%
3M Horizon BME +17.78 pp
BME: +4.95% · BST: -12.83%
6M Horizon BME +24.62 pp
BME: +21.87% · BST: -2.75%
1Y Horizon BME +10.13 pp
BME: +16.71% · BST: +6.58%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BME vs BST. Trailing 12-month operating profitability (BME N/A vs BST N/A) and valuation multiples (BME N/M vs BST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BME ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BST ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BME UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BME Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $487.9M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BST Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $1.4B market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BME vs BST Key Questions & Quantitative Answers

As of Nov 16, 2026, Blackrock Health Sciences Trust (BME) captures the overall head-to-head institutional edge over BlackRock Science and Technology Trust (BST) on higher Unified Composite conviction (40.9/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 2–2 (led by composite factor balance), while BST wins 1–0 across the 6-pillar growth and valuation breakdown. BME trades at $47.08 (N/M Forward P/E, N/A operating margin) versus BST at $43.09 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While BST currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. BME 40.9/100 SELL), BME captures the overall institutional head-to-head verdict (2–2 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: BME trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.7); meanwhile BST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BST leads the Growth & Scale pillar: BME posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BST at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BME generates N/A in USD-normalized revenue versus N/A for BST. In operating R&D and SG&A reinvestment, BME deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BST.

BME and BST trade at balanced relative valuation multiples. BME trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BME (N/A ROE) versus BST (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BME carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.42β · 19% Vol realized risk). By comparison, BST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 41% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.